Should individual PI3 kinase isoforms be targeted in cancer?
- 4 February 2009
- journal article
- review article
- Published by Elsevier in Current Opinion in Cell Biology
- Vol. 21 (2) , 199-208
- https://doi.org/10.1016/j.ceb.2008.12.007
Abstract
No abstract availableKeywords
This publication has 79 references indexed in Scilit:
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesisNature, 2008
- Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repairNature Genetics, 2007
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature, 2007
- High-throughput oncogene mutation profiling in human cancerNature Genetics, 2007
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006
- A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in gliomaCancer Cell, 2006
- Exploiting the PI3K/AKT Pathway for Cancer Drug DiscoveryNature Reviews Drug Discovery, 2005
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004